Our results demonstrate that peripheral blood neutrophils from individuals with AATD have lower levels of the proton channel HVCN1, likely as a result of excess NE and this abnormality is corrected in vivo by AAT augmentation therapy. The gene discussed is HVCN1; the disease is alpha 1-antitrypsin deficiency.